Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at UBS Group from a “neutral” rating to a “buy” rating in a research note issued to investors on Wednesday, April 10th, Marketbeat reports. The brokerage currently has a $77.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $75.00. UBS Group’s price objective points to a potential upside of 14.70% from the company’s current price.
Several other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, April 9th. Maxim Group restated a “buy” rating and set a $84.00 price target on shares of Gilead Sciences in a report on Friday, March 29th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, March 22nd. Oppenheimer set a $85.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th. Finally, BMO Capital Markets started coverage on shares of Gilead Sciences in a research note on Thursday, March 14th. They issued an “outperform” rating and a $78.00 target price on the stock. Nine analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $81.47.
NASDAQ:GILD opened at $67.13 on Wednesday. The company has a quick ratio of 3.30, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. The stock has a market cap of $85.58 billion, a PE ratio of 10.92, a price-to-earnings-growth ratio of 0.85 and a beta of 1.14. Gilead Sciences has a one year low of $60.32 and a one year high of $79.61.
In related news, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the sale, the director now directly owns 143,567 shares in the company, valued at approximately $9,630,474.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total transaction of $186,104.52. Following the sale, the director now owns 57,728 shares in the company, valued at $3,745,969.92. The disclosure for this sale can be found here. Insiders have sold a total of 47,670 shares of company stock worth $3,142,526 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in GILD. Brave Asset Management Inc. bought a new position in shares of Gilead Sciences in the 1st quarter worth $220,000. Goelzer Investment Management Inc. bought a new position in shares of Gilead Sciences in the 1st quarter worth $205,000. WealthTrust Axiom LLC increased its holdings in shares of Gilead Sciences by 9.8% in the 1st quarter. WealthTrust Axiom LLC now owns 21,641 shares of the biopharmaceutical company’s stock worth $1,406,000 after buying an additional 1,937 shares during the last quarter. Stephens Inc. AR increased its holdings in shares of Gilead Sciences by 14.2% in the 1st quarter. Stephens Inc. AR now owns 61,978 shares of the biopharmaceutical company’s stock worth $4,029,000 after buying an additional 7,695 shares during the last quarter. Finally, WestEnd Advisors LLC increased its holdings in shares of Gilead Sciences by 20.2% in the 1st quarter. WestEnd Advisors LLC now owns 535,693 shares of the biopharmaceutical company’s stock worth $34,825,000 after buying an additional 89,886 shares during the last quarter. Institutional investors own 80.27% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Article: What are different types of coverage ratios?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.